Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration – Yahoo Finance

– The study did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks
– Nearly 60% of KSI-301 patients achieved every 5-month dosi… [read more]

Leave a Reply

Your email address will not be published.